To reiterate. ZACKS has Ocugen as a STRONG BUY, with a $1.63 price target: https://www.zacks.com/stock/quote/OCGN?q=OCGN
https://www.zacks.com/stock/news/935314/What-Makes-Ocugen-OCGN-a-New-Strong-Buy-Stock
Even MORE interesting, Zacks has Ocugen rated #10 of 253 companies, in its industry!
Industry Rank:Top 4% (10 out of 253) Industry: Medical - Biomedical and Genetics
Lastly, here is why you need to give the possibility of an Ocugen buyout by, or partnership with, Bausch a little more credibility:
Bausch partnered with Eton Pharmaceuticals to develop a conjunctivitis drug, and, the partnership failed. What is Bausch but an eye company that has FAILED to develop ANY NEW eye drugs:
https://www.bausch.com/our-company/about-bausch-lomb
The suite of Ocugen eye drugs treat a range of eye conditions from dry eye to gene therapy (with prior and pending FDA approvals). Ocugen is EXACTLY the type of company Bausch would target for partnership or buyout.
https://ocugen.com/pipeline/ocunanoe-ocugens-one-platform/
https://ocugen.com/pipeline/ocu200/
https://ocugen.com/pipeline/ocu300/
https://ocugen.com/pipeline/ocu400/
https://ocugen.com/pipeline/ocu410/
https://noble.mediasite.com/Mediasite/Play/9e397dbe17174ae0b92901fcc40988871d
https://ir.ocugen.com/node/8476/pdf
Finally, as this google search reveals, Bausch is not afraid to partner with other companies:
As this list reveals, Bausch is also NOT afraid to buy a company OUT, to get their drugs:
;)
Ocugen is about to finish phase III trials
Fidelity previously added $OCGN to one of their index funds. And, institutionals / large investors have been block buying the HELL out of it. Zacks has $OCGN rated a SUPER BUY, with a $1.63 target:
https://www.zacks.com/stock/quote/OCGN?q=OCGN
Ocugen has at least one drug in phase 3 testing (OCU300), and several pipeline drugs:
https://ocugen.com/pipeline/ocu300/
Specifically, OCU300 was developed from another Ocugen FDA approved drug. And, was entered into an accelerated approval path (excerpt from link above):
Leveraging Ocugens OcuNano technology, OCU300 consists of a proprietary formulation of brimonidine tartrate, an FDA-approved drug with established safety for ocular use, enabling Ocugen to develop OCU300 under the accelerated 505(b)(2) regulatory pathway.
OCU300 entered FDA trials in 2018, and, is getting close to completion of phase 3 of the OCU300 trials:
Estimated Primary Completion Date :
July 2020
Estimated Study Completion Date :
August 2020
https://clinicaltrials.gov/ct2/show/NCT03591874
To reiterate, $OCGN is closing in on the completion of the OCU300 phase III trial, and OCU300 has demonstrated good topline results (re: Page 8):
https://ir.ocugen.com/static-files/f8198c96-a60e-4c55-a4c8-86b2a068f8f0
ALSO, the company just cleaned up its debt situation, while obtaining new funding. Volume has been trending up to 5X AVG on a daily basis, so, it is CLOSE
$OCGN - 50 YEARS OF GUARANTEED REVENUES FROM COVID ANTIBODY TESTING!!!
!!!
INTERNATIONAL
APPROVAL
!!!
GLOBAL REVENUES
!!!
There is an EXISTING partnership for Covid 19 testing between Ocugen and Advaite:
https://advaite.com/pipeline/diagnostics/#
In case you missed it, Ocugen and Advaite are now producing COVID19 tests. There were NO PRs by Ocugen for this!
https://advaite.com/press-release/advaite-deploys-covid-19-rapid-antibody-test-kits-to-chester-county-and-collaborates-with-pennsylvania-companies-to-scale-up-manufacturing/
AND, testing is ramping UP!
https://vista.today/2020/05/after-chester-county-secures-permission-covid-19-antibody-testing-to-begin-at-two-locations/
Emergency Use Authorization (EUA) request for the Rapcov COVID-19 Rapid Test to the FDA (EUA # PEUA200048), currently under FDA review.
https://rapcov.com/fda-status/
FDA EUA Guidelines
https://www.fda.gov/media/135659/download
FDA CV19 Testing FAQ
https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2
One site calls the partnership a rumor and gives insights.
https://markets.businessinsider.com/news/stocks/ocugen-stock-is-question-of-value-1029170325
But, the partnership between Ocugen and Advaite is not rumor, it is fact (re: page 22 of annual report):
https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.
*
There are literally 100s of Covid19 antibody tests. But, there is a VERY SHORT list of RELIABLE, ACCURATE antibody tests:
https://coleofduty.com/news/2020/05/11/global-covid-19-testing-market-2020-size-share-revenue-growth-supply-top-companies-and-forecast-research-2025/
Again, Ocugen has contractually locked in a percentage of ALL Advaite COVID19 Antibody Tests. The revenue stream could encould exceed billions, over the next 20 years. This report answers key questions about this, with regards to Advaite and others. And, to the Ocugen CEO - masterful move sir, to guarantee an indefinite revenue stream for Ocugen like that - MASTERFUL move!
Key questions answered in this report
What will the market size be in 2026 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors?And, these test will become even MORE prevalent, moving forward, as the CDC starts the Covid Surveillance program:
https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-surveillance/index.html
ZACKS UPGRADED TO BUY
ZACKS UPGRADED TO BUY
ZACKS UPGRADED TO BUY
ZACKS UPGRADED TO BUY